Latest Hotspot

Huonslab Reports Positive In Vivo PK Results for Trastuzumab/HyDIFFUZETM vs. Standard Trastuzumab and rHuPH20 Co-formulation

10 September 2024
2 min read

Huonslab, Co. Ltd. ("Huonslab"), a division under Huons Global (KOSDAQ: 084110), has revealed encouraging outcomes from an In Vivo comparative pharmacokinetic (PK) study. The study affirmed the biological equivalence between trastuzumab/HYDIFFUZE and trastuzumab/Enhanze.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Huonslab previously validated the equivalent non-clinical effectiveness of HYDIFFUZE™ compared to Enhanze through a dye dispersion assay in a mouse model, demonstrating it as a locally acting and transient permeation enhancer. Additionally, biological equivalence between rituximab/HYDIFFUZE™ and rituximab/Enhanze was confirmed in a comparative PK study in rats.

Dr. Young Sun Lee, Chief Business Officer at Huonslab, mentioned, “The substance patent for Enhanze has already expired in Europe and South Korea and will expire in the United States in 2027, based on verification by our external patent law firm.”

“With comprehensive FTO analysis and Huonslab's own process patent, we are equipped with unparalleled excellence and rigorous scientific documentation to establish ourselves as a global leader in high concentration antibody formulation (HCAF) for subcutaneous delivery.”

Lee concluded, “We are speeding up the pivotal Phase 1 trial of Hydizyme™, a stand-alone human hyaluronidase drug product, in South Korea, aiming to secure the Biologics License Application (BLA) with MFDS in 2026”

Huonslab will be presenting at the company presentation session during the upcoming BIO Europe 2024 in Stockholm, Sweden.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面

描述已自动生成

According to the data provided by the Synapse Database, As of September 9, 2024, there are 659 investigational drugs for the HER2 targets, including 323 indications, 663 R&D institutions involved, with related clinical trials reaching 3338, and as many as 75980 patents.

Trastuzumab is a monoclonal antibody drug developed by Genentech, Inc. and was first approved for use in the United States in 1998. The drug targets HER2, a protein that is overexpressed in various types of cancer. Trastuzumab has been approved for the treatment of a wide range of cancers, including HER2 positive breast, colorectal, and gastric cancer, as well as salivary gland, lung, ovarian, and pancreatic cancers, among others.

图形用户界面, 文本, 应用程序

描述已自动生成

NextPoint Therapeutics Unveils NPX372, a New T Cell Engager Targeting B7-H7 in Solid Tumors
Latest Hotspot
3 min read
NextPoint Therapeutics Unveils NPX372, a New T Cell Engager Targeting B7-H7 in Solid Tumors
10 September 2024
NextPoint Therapeutics Reveals NPX372, a Novel Drug Targeting B7-H7 in Solid Tumors, as New T Cell Engager.
Read →
Medigene's MDG1015, a Third-Generation T Cell Therapy, Wins FDA Approval for IND Trials in Solid Tumors
Latest Hotspot
4 min read
Medigene's MDG1015, a Third-Generation T Cell Therapy, Wins FDA Approval for IND Trials in Solid Tumors
10 September 2024
Medigene Gets U.S. FDA Approval for IND of MDG1015, a Novel Third Gen T Cell Therapy Targeting Various Solid Tumors.
Read →
Boehringer Ingelheim Advances Promising Geographic Atrophy Therapy Following Positive Phase I Results
Latest Hotspot
4 min read
Boehringer Ingelheim Advances Promising Geographic Atrophy Therapy Following Positive Phase I Results
9 September 2024
Boehringer Ingelheim reveals intention to progress a promising new therapy for Geographic Atrophy, inspired by favorable Phase I outcomes.
Read →
"Overturning" the B7H3 Target: Can Its Potential be Transformed with ADC Drugs?
Hot Spotlight
12 min read
"Overturning" the B7H3 Target: Can Its Potential be Transformed with ADC Drugs?
9 September 2024
B7-H3 (also known as CD276) is a type I transmembrane glycoprotein and a member of the B7 family.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.